Sort   by:  
 Page size 
UnknownPemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Purpose

Cholangiocarcinoma is a rare cancer associated with poor prognosis. Pemigatinib was the first FGFR1-3 inhibitor approved for second-line therapy and beyond, on the basis of the phase II FIGHT-202 trial. Here, we assess efficacy and safety of first-line pemigatinib.

Methods

FIG...
S-EPMC13641261 | biostudies-literature
UnknownDivergent mutational processes distinguish hypoxic and normoxic tumours.
Many primary tumours have low levels of molecular oxygen (hypoxia), and hypoxic tumours respond poorly to therapy. Pan-cancer molecular hallmarks of tumour hypoxia remain poorly understood, with limited comprehension of its associations with specific mutational processes, non-coding driver genes and...
S-EPMC7002770 | biostudies-literature
UnknownGain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice.
Spleen tyrosine kinase (SYK) is a critical immune signaling molecule and therapeutic target. We identified damaging monoallelic SYK variants in six patients with immune deficiency, multi-organ inflammatory disease such as colitis, arthritis and dermatitis, and diffuse large B cell lymphomas. The SYK...
S-EPMC8245161 | biostudies-literature
Sort   by:  
 Page size